title: Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease.
abstract: OBJECTIVE
  There is only little data on immune reconstitution in antiretroviral naive AIDS-patients with toxoplasmosis. The observation of several cases with reduced increase of CD4-cells upon start of antiretroviral treatment (ART) prompted us to investigate the topic using the ClinSurv cohort.
  
  
  METHODS
  17 German HIV treatment centers contribute to ClinSurv, a multicentre observational cohort under the auspices of the Robert Koch Institute. We retrospectively selected all antiretroviral-naive patients with toxoplasmic encephalitis (TE) and - as comparator group - with pneumocystosis (PCP) between January 1999 and December 2005.
  
  
  RESULTS
  A total of 257 patients were included in the analysis, 61 with TE and 196 with PCP. Demographic baseline data showed differences with regard to gender, transmission group, and baseline CD4 superset+ counts (60.9 vs. 44.7/microl, p = 0.022). After ART-initiation the increase in CD4 superset+ lymphocytes was lower in the TE- versus the PCP-group in the first, second and fourth three-month-period (74.4 vs. 120.3/microl, p = 0.006; 96.6 vs. 136.2/microl, p = 0.021; 156.5 vs. 211.5/microl, p = 0.013). Viral load (VL) was higher in the PCP-group at baseline (4.46 log subset10cop/ml vs. 5.00 log subset10cop/ml, p = 0.008), while virological success of ART was equal.
  
  
  CONCLUSIONS
  Our data show for the first time that the average CD4 superset+ T-cell increase of patients with toxoplasmosis is impaired compared to PCP-patients. Most clinicians would not be prepared to discontinue follow-up TE-therapy unless CD4 superset+ counts of 200/microl are reached. Explanation for our finding might be the myelosuppressive side effect of pyrimethamine, possible interactions of toxoplasmosis therapy with ART, or an unknown direct biological influence of toxoplasmosis on immune restoration.
authors.affiliation: Department of Infectious Diseases, University Hospital Munich, Medizinische Poliklinik, Germany. ulrich.kastenbauer@med.uni-muenchen.de
authors.forename: U
authors.initials: U
authors.lastname: Kastenbauer
authors.forename: E
authors.initials: E
authors.lastname: Wolf
authors.forename: C
authors.initials: C
authors.lastname: Kollan
authors.forename: O
authors.initials: O
authors.lastname: Hamouda
authors.forename: J R
authors.initials: JR
authors.lastname: Bogner
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000276:immunology* / Q000821:virology; D012189:Retrospective Studies; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis / Q000276:immunology* / Q000821:virology; D019562:Viral Load